A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Completed · Phase 2

Conditions studied: HCV Infection

In brief

The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).

Key facts

Study ID

NCT00726882

Run by

AbbVie (prior sponsor, Abbott)

People needed

35

Starts

2008-08-01

Expected to finish

2010-05-01

Last updated by the study team

2015-01-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Main Selection Criteria: Subject received ABT-333 or matching placebo in a prior clinical study involving ABT-333.

You may not qualify if…

• The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in prior ABT-333 clinical study.

Where it is running

• Site Reference ID/Investigator# 17665 — Anaheim, California, United States
• Site Reference ID/Investigator# 17367 — Los Angeles, California, United States
• Site Reference ID/Investigator# 17672 — Los Angeles, California, United States
• Site Reference ID/Investigator# 10381 — Orlando, Florida, United States
• Site Reference ID/Investigator# 17667 — Baton Rouge, Louisiana, United States
• Site Reference ID/Investigator# 14461 — San Antonio, Texas, United States
• Site Reference ID/Investigator# 11141 — Santurce, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.